The role of nurse navigators has grown exponentially in recent years, and is now regarded as an integral element of oncology treatment and patient care. The Academy of Oncology Nurse & Patient Navigators (AONN+) defines patient navigation as the “process whereby a patient is given individualized support across the continuum of care, beginning with community outreach to raise awareness and perform cancer screening, through the diagnosis and treatment process, and on to short- and long-term survivorship or end of life.” At the Best Practices in Lung Cancer Navigation Summit, held October 22, 2016, in Rosemont, IL, oncology nurse navigators involved in the care of patients with lung cancer convened to discuss the complexities and role of nurse navigators in the treatment of lung cancer.
Immune-related toxicities in patients with NSCLC can be traced back to the mechanism of action of immune checkpoint inhibitors.
When added to treatment with docetaxel, the investigational drug plinabulin improved overall survival by 4.7 months in patients with advanced non–small-cell lung cancer with measurable lesions.
Projected Long-Term Survival High for Patients with Advanced Non–Small-Cell Lung Cancer Treated with Pembrolizumab
Durability of benefit (ie, the possibility for sustained remission in patients with previously incurable disease) is already one of the hallmarks of immunotherapy. According to a recent statistical analysis, however, this durability even exceeded expectations.
Dr. Edward Garon discusses the importance of smoking cessation programs for patients diagnosed with lung cancer.
Dr. Edward Garon talks about the best approaches for screening patients for lung cancer.
Dr. Edward Garon identifies the target population for lung cancer screening.
Dr. Edward Garon provides an overview of the most common presenting clinical features in adults with non-small cell lung cancer (NSCLC).
Dr. Edward Garon reviews how certain drugs can change the landscape for treating patients with lung cancer.
Dr. Edward Garon discusses the use of PD-1 and PD-L1 inhibitors in patients with lung cancer.
Page 1 of 6
Results 1 - 10 of 57
Results 1 - 10 of 57